Spectrum files belinostat NDA in rare lymphoma
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals submitted a new drug application (NDA) to the US FDA seeking accelerated approval for belinostat in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) based on Phase II results for the pan-histone deacetylase (HDAC) inhibitor.